MRCP Part 1 → Psychiatry
Psychiatry accounts for roughly 4.5% of the MRCP Part 1 blueprint. This bank has 135 items tagged to it.
Around 4.5% of the paper, per MRCP(UK) examination blueprints and regulations. That weighting is why the DocPasser mock builder samples sections in proportion rather than shuffling everything into one pile — practising a flat distribution trains you for a paper that does not exist.
A 26-year-old man is brought in by family after a week of barely sleeping, talking rapidly, spending large sums he cannot afford and claiming he will transform the city. He is elated and irritable, with grandiose plans and no insight. He had an episode of severe depression two years ago. What is the most likely diagnosis?
The point: Bipolar affective disorder is a mood disorder characterised by recurrent episodes of both depression and mania or hypomania. A manic episode is a distinct period of abnormally elevated, expansive or irritable mood lasting at least a week, with features such as inflated self-esteem or grandiosity, reduced need for sleep, pressure of speech, flight of ideas, distractibility, increased goal-directed activity and risk-taking (overspending, disinhibition), and psychotic features can occur; it causes marked impairment or needs admission. Hypomania is a milder form without psychosis or severe impairment. Bipolar I is defined by at least one manic episode, and bipolar II by hypomania with depression. The differential includes unipolar depression (so a depressed patient should be asked about past highs before an antidepressant is started, because antidepressants alone can precipitate mania or rapid cycling), schizoaffective disorder, drug-induced states and organic causes. Management combines pharmacological and psychological care under specialist services: acute mania is treated with an antipsychotic (and any antidepressant is stopped), while long-term relapse prevention uses a mood stabiliser, with lithium being the most effective, requiring monitoring of levels, renal and thyroid function. Depression in bipolar disorder is treated cautiously to avoid switching. Risk assessment is central because of the risks of harm during both manic and depressive phases.
Source: NICE CG185 — bipolar disorder: assessment and management NICE · tier 1, national regulator or guidance
A 26-year-old man is brought in by family after a week of barely sleeping, talking rapidly, spending large sums he cannot afford and claiming he will transform the city. He is elated and irritable, with grandiose plans and no insight. He had an episode of severe depression two years ago. What is the most appropriate investigation?
The point: Bipolar affective disorder is a mood disorder characterised by recurrent episodes of both depression and mania or hypomania. A manic episode is a distinct period of abnormally elevated, expansive or irritable mood lasting at least a week, with features such as inflated self-esteem or grandiosity, reduced need for sleep, pressure of speech, flight of ideas, distractibility, increased goal-directed activity and risk-taking (overspending, disinhibition), and psychotic features can occur; it causes marked impairment or needs admission. Hypomania is a milder form without psychosis or severe impairment. Bipolar I is defined by at least one manic episode, and bipolar II by hypomania with depression. The differential includes unipolar depression (so a depressed patient should be asked about past highs before an antidepressant is started, because antidepressants alone can precipitate mania or rapid cycling), schizoaffective disorder, drug-induced states and organic causes. Management combines pharmacological and psychological care under specialist services: acute mania is treated with an antipsychotic (and any antidepressant is stopped), while long-term relapse prevention uses a mood stabiliser, with lithium being the most effective, requiring monitoring of levels, renal and thyroid function. Depression in bipolar disorder is treated cautiously to avoid switching. Risk assessment is central because of the risks of harm during both manic and depressive phases.
Source: NICE CG185 — bipolar disorder: assessment and management NICE · tier 1, national regulator or guidance
A 26-year-old man is brought in by family after a week of barely sleeping, talking rapidly, spending large sums he cannot afford and claiming he will transform the city. He is elated and irritable, with grandiose plans and no insight. He had an episode of severe depression two years ago. What is the most appropriate management?
The point: Bipolar affective disorder is a mood disorder characterised by recurrent episodes of both depression and mania or hypomania. A manic episode is a distinct period of abnormally elevated, expansive or irritable mood lasting at least a week, with features such as inflated self-esteem or grandiosity, reduced need for sleep, pressure of speech, flight of ideas, distractibility, increased goal-directed activity and risk-taking (overspending, disinhibition), and psychotic features can occur; it causes marked impairment or needs admission. Hypomania is a milder form without psychosis or severe impairment. Bipolar I is defined by at least one manic episode, and bipolar II by hypomania with depression. The differential includes unipolar depression (so a depressed patient should be asked about past highs before an antidepressant is started, because antidepressants alone can precipitate mania or rapid cycling), schizoaffective disorder, drug-induced states and organic causes. Management combines pharmacological and psychological care under specialist services: acute mania is treated with an antipsychotic (and any antidepressant is stopped), while long-term relapse prevention uses a mood stabiliser, with lithium being the most effective, requiring monitoring of levels, renal and thyroid function. Depression in bipolar disorder is treated cautiously to avoid switching. Risk assessment is central because of the risks of harm during both manic and depressive phases.
Source: NICE CG185 — bipolar disorder: assessment and management NICE · tier 1, national regulator or guidance
Clinical sciences · Clinical pharmacology and therapeutics · Cardiology · Respiratory medicine · Gastroenterology and hepatology · Neurology · Endocrinology, diabetes and metabolic medicine · Renal medicine · Infectious diseases · Rheumatology · Haematology · Dermatology · Geriatric medicine · Oncology · Medical ophthalmology · Palliative medicine and end of life care